MedTrace Logo

Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

NCT00394472 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2013-03-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.

Conditions

  • Gastroesophageal Reflux Disease (GERD)

Interventions

DRUG

AZD3355

Sponsors & Collaborators

Principal Investigators

  • Göran Hasselgren, MD · AstraZeneca

  • Guy Boeckxstaens, MD · Academisch Medisch Centrum Universiteit van Amsterdam

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • Australia
  • Belgium
  • France
  • Germany
  • Hungary
  • Netherlands
  • Norway
  • Romania

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00394472 on ClinicalTrials.gov